How different ways of drawing blood from a central line compare for heparin activity
Part of Blood & lymphatic, Heart & circulation clinical trials.
This trial checks whether blood samples taken from a central line using either a syringe flush or a vacuum tube give the same heparin activity results as blood from a vein in the arm. It is designed for patients in the ICU who are on a steady heparin drip.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You are currently in the intensive care unit (ICU)
- You have a central line (a special IV placed in a large vein in the neck, chest, or groin) with at least three ports
- You are receiving a continuous heparin drip, and your target Anti-Xa level (a test for blood thinning) is between 0.3 and 0.7 IU/ml
- You are able to give consent or have someone do it for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two doses of a blood thinner (enoxaparin) to see which better prevents blood clots in patients with severe injuries who are in the intensive care unit. It helps doctors choose the best dose to keep you safe and healthy.
This trial compares using heparin (a blood-thinning medicine) versus saline (salt water) to keep a peripheral IV line open and working. It may help reduce line blockage and improve how well IV treatments can be given.
This trial tests whether giving a blood thinner before placing a central line (a special IV) helps prevent clots in critically ill children. It could lower the risk of problems from the line.
This study tests different ways to measure the level of blood thinner (unfractionated heparin) in children's blood while they are in intensive care after heart surgery. The goal is to find the most accurate method so doctors can give the right dose and keep children safe.
This trial tests whether starting enoxaparin (a blood-thinner) within 24 hours after placing a specific type of central line can prevent dangerous clots. It may help reduce clot risk in people whose line is placed in the neck or thigh vein, while also tracking bleeding side effects.
This trial tests whether giving heparin (a blood thinner) during a specific type of heart procedure is safer and works better than not giving it. It focuses on patients where the blood supply in the hand’s artery connection is functioning properly.
Hear when a new Anticoagulants and Bleeding Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.